Iqvia (NYSE:IQV) PT Raised to $195.00

Share on StockTwits

Iqvia (NYSE:IQV) had its price objective lifted by stock analysts at Citigroup from $185.00 to $195.00 in a note issued to investors on Thursday, The Fly reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Citigroup‘s price objective indicates a potential upside of 18.67% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating and set a $170.00 price target for the company in a research note on Tuesday, February 4th. Credit Suisse Group restated a “buy” rating and issued a $170.00 price target on shares of Iqvia in a research note on Friday, December 20th. Wells Fargo & Co assumed coverage on Iqvia in a research note on Tuesday, January 7th. They issued an “overweight” rating and a $180.00 price target for the company. Wolfe Research upgraded Iqvia from a “peer perform” rating to an “outperform” rating in a research note on Thursday, November 14th. Finally, Cfra upgraded Iqvia from a “hold” rating to a “buy” rating and boosted their price target for the stock from $148.00 to $185.00 in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Iqvia has an average rating of “Buy” and an average price target of $174.30.

IQV stock opened at $164.32 on Thursday. Iqvia has a 1-year low of $130.77 and a 1-year high of $169.14. The business has a fifty day moving average price of $158.20 and a 200-day moving average price of $151.72. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.05 and a quick ratio of 1.12. The stock has a market capitalization of $32.17 billion, a P/E ratio of 28.53, a P/E/G ratio of 1.76 and a beta of 0.91.

Iqvia (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Iqvia had a return on equity of 17.65% and a net margin of 1.72%. The firm had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the business earned $1.50 earnings per share. The company’s revenue was up 7.7% on a year-over-year basis. As a group, analysts anticipate that Iqvia will post 6.81 earnings per share for the current year.

In related news, CFO Michael R. Mcdonnell sold 12,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the completion of the sale, the chief financial officer now owns 14,366 shares in the company, valued at $2,227,735.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Evanisko sold 6,250 shares of the company’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $160.76, for a total value of $1,004,750.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,000 shares of company stock valued at $5,830,215. 6.00% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. Penserra Capital Management LLC increased its position in Iqvia by 57.5% during the fourth quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Dai Ichi Life Insurance Company Ltd increased its position in Iqvia by 0.3% during the fourth quarter. Dai Ichi Life Insurance Company Ltd now owns 24,313 shares of the medical research company’s stock valued at $3,757,000 after acquiring an additional 72 shares during the last quarter. Hall Laurie J Trustee increased its position in Iqvia by 14.2% during the fourth quarter. Hall Laurie J Trustee now owns 605 shares of the medical research company’s stock valued at $93,000 after acquiring an additional 75 shares during the last quarter. Montag & Caldwell LLC increased its position in Iqvia by 3.3% in the third quarter. Montag & Caldwell LLC now owns 2,840 shares of the medical research company’s stock worth $424,000 after buying an additional 90 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in Iqvia by 0.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 15,925 shares of the medical research company’s stock worth $2,460,000 after buying an additional 93 shares in the last quarter. Institutional investors own 89.93% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: Support Level

The Fly

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.